Last reviewed 2026-04-20 · How we verify

Estradurin (POLYESTRADIOL PHOSPHATE)

Estradurin, also known as Polyestradiol Phosphate, is a synthetic estrogen medication that targets the estrogen receptor. Originally developed and currently owned by various companies, it was first approved by the FDA in 1957 for the treatment of certain conditions. As an off-patent medication, Estradurin is no longer protected by patents, allowing generic manufacturers to produce it. However, there are currently no generic manufacturers of Estradurin. It is classified as an estrogen and works as a small molecule modality.

At a glance

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

• Open Label, Sequential Dosing , Single Ascending Dose and Multiple Dose Safety Tolerability and Pharmacokinetic Study (PHASE1)
• Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy (PHASE2)
• Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer (PHASE2)
• Hormone Therapy Compared With Combination Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
• Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse (PHASE3)
• Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
• Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer (PHASE3)
• Evaluation of the Efficacy of Estramustine in Patient With Breast Cancer Progression After Treatment With Aromatase Inhibitor. (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.